Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
Stocktwits on MSN
Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive DisorderThe new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback